Cargando…
In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium
Mycoplasma genitalium has developed resistance to first-line azithromycin and second-line moxifloxacin. Third-line pristinamycin is only 75% effective. Gepotidacin, a novel triazaacenaphthylene topoisomerase II inhibitor, blocks bacterial DNA replication. We determined the in vitro activity of gepot...
Autores principales: | Jensen, Jørgen Skov, Nørgaard, Christina, Scangarella-Oman, Nicole, Unemo, Magnus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473033/ https://www.ncbi.nlm.nih.gov/pubmed/32552547 http://dx.doi.org/10.1080/22221751.2020.1775498 |
Ejemplares similares
-
Doxycycline and Sitafloxacin Combination Therapy for Treating Highly Resistant Mycoplasma genitalium
por: Durukan, Duygu, et al.
Publicado: (2020) -
Azithromycin and Doxycycline Resistance Profiles of U.S. Mycoplasma genitalium Strains and Their Association with Treatment Outcomes
por: Wood, Gwendolyn E., et al.
Publicado: (2021) -
Mycoplasma genitalium: whole genome sequence analysis, recombination and population structure
por: Fookes, Maria C., et al.
Publicado: (2017) -
724. The In Vitro Activity of Gepotidacin and Comparator Agents Against Anaerobic Bacterial Isolates
por: Hackel, Meredith, et al.
Publicado: (2019) -
Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants
por: Barth, Aline, et al.
Publicado: (2022)